The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on ...

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

Can I go to Europe this summer? 2021? The New York Times Article: <a href=" The playlist <a href=" YEAH!!! Europe is open to ...

Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with ...

Reviving UK investment is among the most pressing challenges facing Britain. Rachel Reeves plans to raise the issue in her ...

Biocon Biologics was granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, for treating bone diseases and related conditions ...

Denosumab biosimilars Vevzuo and Evfraxy are used for treating various bone diseases. The approvals mark a key step in the ...

Biocon Biologics gets EU approval for Denosumab biosimilars Vevzuo & Evfraxy, expanding access to bone disease treatments across Europe.

Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars ...